Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01932528 | An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males | PHASE1 | COMPLETED | 8 | — | — | Aug 1, 2013 | - | Oct 23, 2013 | 1 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| 500 mg LX606 | EXPERIMENTAL | All subjects will receive a single oral 500 mg dose of \[14C\]-LX1606. |
| Name | Type | Description |
|---|---|---|
| 500 mg [14C]-LX1606 | DRUG | 500 mg dose of LX1606 containing a target dose of 3.32 Megabecquerel (MBq) of radiation as \[14C\]-LX1606. |
Inclusion Criteria: * Healthy male subjects aged 30 to 65 years of age. * Male subjects and their partners must agree to use an adequate method of contraception * Historically able to produce a minimum of 1 bowel movement every day on most days Exclusion Criteria: * Female subjects * Use of any m...